Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.31 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.31 |
| ▸ | ESRRB | O95718 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | ESRRA | P11474 | 1/20 | 0.30 |
| ▸ | ESRRG | P62508 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.30 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.30 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1979175 | 0.80 | AR (0.44) | SRCSYKMAPK12ESRRBESR1 | |
| SCHEMBL18952970 | 0.80 | AR (0.36) | SRCSYKMAPK12TRPV4ESRRB | |
| SCHEMBL18952957 | 0.80 | ROCK2 (0.31) | SRCSYKMAPK12TRPV4ESRRB | |
| SCHEMBL30939539 | 0.78 | ELANE (0.35) | TRPV4ESRRBESR1ESRRAESRRG | |
| SCHEMBL1979370 | 0.78 | ELANE (0.35) | TRPV4ESRRBESR1ESRRAESRRG | |
| SCHEMBL18952974 | 0.76 | MMP13 (0.33) | SRCSYKMAPK12TRPV4ESRRB | |
| SCHEMBL19011617 | 0.76 | AR (0.35) | SRCSYKMAPK12ESRRBESR1 | |
| SCHEMBL19805323 | 0.75 | PTGDR2 (0.38) | TRPV4HSD11B1HSD11B2NR3C1 | |
| SCHEMBL1979583 | 0.74 | ELANE (0.33) | SRCSYKMAPK12HSD11B1SSTR4 | |
| SCHEMBL29437994 | 0.74 | ELANE (0.33) | SRCSYKMAPK12HSD11B1SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180021336-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180021336-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | KCND3, KCNK3, KCNA3 | SRC 4241/4885SYK 3336/4885MAPK12 1951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.